博瑞医药
(688166)
| 流通市值：151.26亿 | | | 总市值：151.26亿 |
| 流通股本：4.36亿 | | | 总股本：4.36亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 678,096,598.23 | 324,934,750.4 | 1,223,640,129.98 | 874,249,705.24 |
| 营业收入 | 678,096,598.23 | 324,934,750.4 | 1,223,640,129.98 | 874,249,705.24 |
| 二、营业总成本 | 615,978,033.86 | 329,340,975.82 | 1,204,341,010.5 | 859,671,361.36 |
| 营业成本 | 303,288,733.36 | 140,464,532.97 | 601,611,553.11 | 424,926,677.5 |
| 税金及附加 | 8,462,685.92 | 3,642,886.72 | 13,029,854.37 | 8,904,941.78 |
| 销售费用 | 15,974,946.57 | 12,018,781.88 | 78,021,529.36 | 61,771,544.27 |
| 管理费用 | 72,546,014.23 | 32,025,530.98 | 154,505,701.98 | 113,542,725.05 |
| 研发费用 | 171,055,028.09 | 120,151,095.89 | 304,947,050.73 | 216,428,186.84 |
| 财务费用 | 44,650,625.69 | 21,038,147.38 | 52,225,320.95 | 34,097,285.92 |
| 其中:利息费用 | 38,649,563.65 | 18,582,633.2 | 62,957,015.06 | 48,369,730.43 |
| 其中:利息收入 | 1,362,390.92 | 311,493.41 | 5,547,241.5 | 7,958,528.43 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 18,727,936.8 | 2,589,650.9 | 13,784,762.71 | 1,513,855.64 |
| 加:投资收益 | -3,529,898.35 | -796,203.85 | -19,321,426.73 | -11,753,984.38 |
| 资产处置收益 | 8,824.6 | - | - | - |
| 资产减值损失(新) | -3,436,773.54 | 729,415.71 | -17,497,638.54 | -2,756,862.56 |
| 信用减值损失(新) | -23,218,352.97 | -8,653,096.6 | -20,274,363.81 | 3,127,119.97 |
| 其他收益 | 10,141,189.14 | 6,847,801.56 | 38,673,662.95 | 18,064,813.94 |
| 四、营业利润 | 60,811,490.05 | -3,688,657.7 | 14,664,116.06 | 22,773,286.49 |
| 加:营业外收入 | 268,937.77 | 263,079.51 | 207,522.2 | 178,434.88 |
| 减:营业外支出 | 79,482.36 | 51,321.48 | 962,807.6 | 536,922.71 |
| 五、利润总额 | 61,000,945.46 | -3,476,899.67 | 13,908,830.66 | 22,414,798.66 |
| 减:所得税费用 | -3,483,494.66 | -12,978,304.71 | -23,045,408.52 | -8,971,726.09 |
| 六、净利润 | 64,484,440.12 | 9,501,405.04 | 36,954,239.18 | 31,386,524.75 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 64,484,440.12 | 9,501,405.04 | 36,954,239.18 | 31,386,524.75 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 58,932,817.33 | 9,293,715.39 | 54,514,680.92 | 50,320,017.34 |
| 少数股东损益 | 5,551,622.79 | 207,689.65 | -17,560,441.74 | -18,933,492.59 |
| 扣除非经常损益后的净利润 | 32,692,905.92 | 4,211,386.68 | 26,089,388.86 | 46,172,260.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.02 | 0.13 | 0.12 |
| (二)稀释每股收益 | 0.14 | 0.02 | 0.13 | 0.12 |
| 八、其他综合收益 | 3,101,668.36 | -327,248 | 36,676,515.56 | -2,579,713.14 |
| 归属于母公司股东的其他综合收益 | 3,101,668.36 | -327,248 | 36,676,515.56 | -2,579,713.14 |
| 九、综合收益总额 | 67,586,108.48 | 9,174,157.04 | 73,630,754.74 | 28,806,811.61 |
| 归属于母公司股东的综合收益总额 | 62,034,485.69 | 8,966,467.39 | 91,191,196.48 | 47,740,304.2 |
| 归属于少数股东的综合收益总额 | 5,551,622.79 | 207,689.65 | -17,560,441.74 | -18,933,492.59 |
| 公告日期 | 2026-08-31 | 2026-04-30 | 2026-03-20 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |